ChristopherPleyerMD

Hematology • Bethesda, MD

Clotting Disorder

Physician

Join to view full profile

Dr. Pleyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pleyer's full profile

Already have an account?

Office
10 Center Dr
Bethesda, MD 20814
Phone+1 216-444-2200

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
Cleveland Clinic FoundationResidency, Internal Medicine, 2013 - 2016
OtherClass of 2012

Certifications & Licensure

CA State Medical License 2018 - 2026
DC State Medical License 2018 - 2024
OH State Medical License 2013 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

1 citations
Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
Emily Tomasulo, Shira Paul, Rui Mu, Xin Tian, Jonathan Chen
Leukemia & Lymphoma. 2023-12-01
17 citations
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL.
Christopher Pleyer, Kerry J Laing, Mir A Ali, Christopher L McClurkan, Susan Soto
Blood Advances. 2022-03-22
17 citations
COVID-19 vaccines for patients with haematological conditions.
Clare Sun, Christopher Pleyer, Adrian Wiestner
The Lancet. Haematology. 2021-03-31

Lectures

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's T...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018